Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quidel appoints Mason CEO

This article was originally published in The Gray Sheet

Executive Summary

Caren Mason assumes beleaguered point-of-care rapid diagnostic test firm's top spot Aug. 20, replacing Wayne Kay (1"The Gray Sheet" July 19, 2004, p. 24). Mason brings over 25 years of healthcare experience to the Quidel post, ranging from service as CEO of two digital technology start-ups, eMed Technologies and MiraMedica, to running GE Medical Systems' Women's Healthcare business. Initially, she plans to focus on building Quidel R&D initiatives and solidifying relationships with end-users...

You may also be interested in...



People In Brief

Alcon President & CEO: Cary Rayment plans to build Alcon's international surgical and pharmaceutical businesses in Asia after assuming the joint position Oct. 1. He will seek further expansion into Japan, the firm's second largest market behind the U.S., as well as China, Korea and India. Rayment, 57, will replace Tim Sear, 67, who has been with Alcon 34 years and saw the firm through its 2002 initial public offering. In 2001, Rayment became senior-VP, directing cross-divisional efforts for surgical, pharmaceutical and consumer groups in the U.S. In January, he took responsibility for Alcon Japan. Rayment has been with Alcon since it acquired CooperVision Surgical in 1989. Kevin Buehler, 47, a 20-year Alcon veteran and VP-operations, Latin America, Canada and the Far East, will replace Rayment...

Health And Wellness Trademark Review 1 December, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Ipsen CEO Outlines Strategy For Long-Term Success

While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel